Synaptogenix Files 8-K on Security Holder Votes

TL;DR

Synaptogenix filed an 8-K for security holder votes - details TBD.

AI Summary

Synaptogenix, Inc. filed an 8-K on December 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official notification of these events.

Why It Matters

This filing indicates that Synaptogenix, Inc. has held or is holding votes among its security holders, which could pertain to significant corporate actions or governance changes.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

• Synaptogenix, Inc. (company) — Registrant
• December 6, 2024 (date) — Date of earliest event reported
• 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 (location) — Principal executive offices address
• NEUROTROPE BIOSCIENCE, INC. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq

Filing Documents

• tm2430385d1_8k.htm (8-K) — 35KB
• 0001104659-24-126355.txt ( ) — 208KB
• snpx-20241206.xsd (EX-101.SCH) — 3KB
• snpx-20241206_lab.xml (EX-101.LAB) — 33KB
• snpx-20241206_pre.xml (EX-101.PRE) — 22KB
• tm2430385d1_8k_htm.xml (XML) — 4KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 6, 2024, Synaptogenix, Inc. ("we," "us" and "our") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the holders of 846,988 shares of our Common Stock, or approximately 54.03% of our outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered four proposals, which are described briefly below and in more detail in the Proxy Statement. The final voting results for each proposal are set forth below. Proposal 1 - Election of Directors Our stockholders voted to elect two directors to hold office until the 2027 annual meeting of stockholders, and until their respective successors are elected and qualified, by the following votes: Nominee For Withheld Broker Non-Votes Joshua Silverman 369,569 109,201 368,218 William S. Singer 367,990 110,780 368,218 Proposal 2 - Board Authorization to Issue Stock Pursuant to Securities Purchase Agreement Our stockholders voted to authorize our board of directors (the "Board") to issue shares of the Company's common stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of a Securities Purchase Agreement, dated September 10, 2024, in an amount equal to or in excess of 20% of our common stock outstanding Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 246,470 100,776 14,180 485,562 Proposal 3 - Approval of Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan Our stockholders voted to approve an amendment to our Plan to increase the total number of shares of Common Stock authorized for issuance thereunder from 175,000 shares of Common Stock to an aggregate of 675,000 shares of Common Stock by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 270,829 194,62

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: December 6, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR